{"id":"W4290190465","doi":"10.1007/s13555-022-00764-4","title":"Durability of Response to Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis After Treatment Discontinuation in a Phase 2b Trial","year":2022,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"ca_institutions":"Innovaderm (Canada); SKiN Health","funders":"Pfizer","keywords":"Eczema Area and Severity Index; Discontinuation; Medicine; Atopic dermatitis; Placebo; Internal medicine; SCORAD; Gastroenterology; Dermatology; Disease; Dermatology Life Quality Index; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003405615,0.0006534296,0.00174732,0.0002462683,0.0003815868,0.001077075,0.0004461367,0.0008396104,0.003107704],"category_scores_gemma":[0.001558816,0.0002224353,0.001336144,0.0003174619,0.0003432917,0.0006294654,0.0002385861,0.001705511,0.0006029207],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004138888,"about_ca_system_score_gemma":0.0005344394,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000177594,"about_ca_topic_score_gemma":0.0005078999,"domain_scores_codex":[0.9991196,0.0004048958,0.00006837343,0.0001613502,0.0001030727,0.0001427432],"domain_scores_gemma":[0.9988756,0.0003124197,0.0003233586,0.0001023414,0.00008310873,0.0003031589],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.7842525,0.008796639,0.03249688,0.001755252,0.00427904,0.0003434895,0.0002380975,0.0008132799,0.01485098,0.0002069851,0.004401314,0.1475655],"study_design_scores_gemma":[0.6042758,0.2453182,0.1341036,0.000260499,0.002242966,0.00105819,0.00008842266,0.001318965,0.002958313,0.0005415674,0.007778272,0.00005526593],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9841648,0.0110449,0.0003361424,0.0004715388,0.0001540003,0.0007356533,0.0007976666,0.00007207921,0.0022232],"genre_scores_gemma":[0.9946426,0.001712388,0.0003206397,0.000584401,0.0001877747,0.0006859892,0.0009067466,0.0000109732,0.0009482973],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003405615,"threshold_uncertainty_score":0.01801085,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01116380970342414,"score_gpt":0.2820543683081328,"score_spread":0.2708905586047087,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}